DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours by Zhang, Hanwen et al.
ORIGINAL ARTICLE
DOTA-PESIN, a DOTA-conjugated bombesin derivative
designed for the imaging and targeted radionuclide
treatment of bombesin receptor-positive tumours
Hanwen Zhang & Jochen Schuhmacher &
Beatrice Waser & Damian Wild & Michael Eisenhut &
Jean Claude Reubi & Helmut R. Maecke
Received: 13 June 2006 /Accepted: 17 November 2006 / Published online: 30 January 2007
# Springer-Verlag 2007
Abstract
Purpose We aimed at designing and developing a novel
bombesin analogue, DOTA-PEG4-BN(7–14) (DOTA-PESIN),
with the goal of labelling it with 67/68Ga and 177Lu for
diagnosis and radionuclide therapy of prostate and other
human cancers overexpressing bombesin receptors.
Methods The 8-amino acid peptide bombesin (7–14) was
coupled to the macrocyclic chelator DOTA via the spacer
15-amino-4,7,10,13-tetraoxapentadecanoic acid (PEG4).
The conjugate was complexed with Ga(III) and Lu(III)
salts. The GRP receptor affinity and the bombesin receptor
subtype profile were determined in human tumour speci-
mens expressing the three bombesin receptor subtypes.
Internalisation and efflux studies were performed with the
human GRP receptor cell line PC-3. Xenografted nude
mice were used for biodistribution.
Results [GaIII/LuIII]-DOTA-PESIN showed good affinity to
GRP and neuromedin B receptors but no affinity to BB3.
[67Ga/177Lu]-DOTA-PESIN internalised rapidly into PC-3
cells whereas the efflux from PC-3 cells was relatively
slow. In vivo experiments showed a high and specific
tumour uptake and good retention of [67Ga/177Lu]-DOTA-
PESIN. [67Ga/177Lu]-DOTA-PESIN highly accumulated in
GRP receptor-expressing mouse pancreas. The uptake
specificity was demonstrated by blocking tumour uptake
and pancreas uptake. Fast clearance was found from blood
and all non-target organs except the kidneys. High tumour-
to-normal tissue ratios were achieved, which increased with
time. PET imaging with [68Ga]-DOTA-PESIN was success-
ful in visualising the tumour at 1 h post injection. Planar
scintigraphic imaging showed that the 177Lu-labelled
peptide remained in the tumour even 3 days post injection.
Conclusion The newly designed ligands have high poten-
tial with regard to PET and SPECT imaging with 68/67Ga
and targeted radionuclide therapy with 177Lu.
Keywords Gallium-68 . Lutetium-177 .
Bombesin receptors . Targeted radiotherapy .
Prostate cancer
Introduction
Radionuclides coupled to receptor-specific peptides are
currently under investigation in clinical trials involving
different tumours [1]. They specifically localise receptors
overexpressed on the plasma membrane and then internalise
into cells [2–4]. The prototypes of these peptides are
analogues of somatostatin [5].
In designing radiometal-based radiopeptides for cancer
diagnosis and treatment, important factors to consider are
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half-life, mode of decay, cost and availability of the
radionuclide. In diagnostic imaging [6], 99mTc, 123I, 67Ga
and 111In are used for SPECT and 18F, 11C, 64Cu and 68Ga
for positron emission tomography (PET). 177Lu-labelled
peptides have become attractive in targeted radiotherapy of
small tumours or metastases owing to their excellent
radiophysical properties and commercial availability of the
radionuclide [5, 7, 8]. 68Ga, on the other hand, is a
promising metallic positron emitter (t1/2=68 min, 89%,
Eβ
+
max=1.90 MeV) for regular use in PET imaging because
of its production from a 68Ga/68Ge generator, which allows
independence from an on-site cyclotron and offers almost
unlimited availability if two or three of these generators are
used concomitantly as elution is possible every 3 h [9, 10].
To develop a ligand for the labelling with these two
radionuclides would therefore seem promising.
In the field of radiolabelled peptides, bombesin (BN)
analogues have become a promising class of ligands as
gastrin-releasing peptide (GRP) receptors, a subtype of BN
receptors, were found to be overexpressed on primary
prostatic invasive carcinoma (and their invaded lymph
nodes), breast tumours and gastrointestinal stromal tumours
[11]. Up to now, many types of radiolabelled BN analogues
have been designed to target GRP receptor-expressing
tumours [12–24]. In particular, Van de Wiele et al. reported
on a first study of prostate (n=4) and breast cancer (n=6)
patients [13, 25]. Their results showed that 99mTc-RP527
visualised four of six breast and one of four prostate
carcinomas. This radiopeptide showed inferior properties to
many other radiopeptides in the PC-3 tumour-bearing nude
mouse model [26]. As 99mTc-Demobesin 1 ([99mTc-N40–1,
bzlg0,(D)Phe6,Leu-NHEt13,des-Met14]BN(6–14)) has
shown higher affinity to the GRP receptor and a higher
tumour accumulation in PC-3 tumour-bearing mice [27]
than 99mTc-RP527, it may be a superior candidate for
studying in patients.
We have recently developed DOTA (1,4,7,10-tetraaza-
cyclododecane-1,4,7,10-tetraacetic acid)- and DTPA-modi-
fied (pan)BN radioligands having high affinity to all three
human BN receptors [i.e. neuromedin B receptor (NMB-R),
GRP-R and BN receptor subtype-3 (BB3)] [17]. Prelimi-
nary results in clinical studies of two of these radiopeptides
have shown occasional uptake in the pancreas and relatively
fast washout from lesions when labelled with 111In. The fast
washout may be due to a low metabolic stability of these
radiopeptides. Therefore, we set up a programme to
synthesise BN-based radiopeptides with improved meta-
bolic stability, an optimised tumour-to-kidney ratio and lack
of affinity to BB3. From a series of peptides evaluated,
DOTA-PEG4-BN(7–14) (DOTA-PESIN) looked particular-
ly promising in our preclinical studies.
Here we present data on the synthesis and labelling of
this peptide with the positron emitter 68Ga, the γ- and
Auger electron emitter 67Ga and the β(γ)-emitter 177Lu. In
addition, we studied the receptor subtype affinity profile
and the in vivo biodistribution of radiolabelled DOTA-
PESIN with regard to BN receptor subtypes. PET imaging
and scintigraphy were also performed.
Materials and methods
All chemicals were obtained from commercial sources and
used without further purification. Rink amide 4-methyl-
benzhydrylalanine (MBHA) resin and all Fmoc-protected
amino acids are commercially available from NovaBiochem
(Laeufelfingen, Switzerland). [67Ga]Cl3 was purchased
from Mallinckrodt Medical (Petten, the Netherlands) and
[177Lu]Cl3 from IDB (Petten, the Netherlands). Fmoc-15-
amino-4,7,10,13-tetraoxapentadecanoic acid (Fmoc-PEG4 -
OH) was obtained from Quanta BioDesign (Powell, Ohio,
USA) and 1,4,7,10-tetraazacyclododecane-1,4,7-tris(acetic
acid-t-butyl ester)-10-acetic acid [DOTA-tris(tBu ester)]
from Macrocyclics (Dallas, Texas, USA). Electrospray
ionisation mass spectroscopy was carried out with a
Finnigan SSQ 7,000 spectrometer (Bremen, Germany) and
MALDI-MS measurement on a Voyager sSTR equipped
with an Nd:YAG laser (Applied Biosystems, Framingham,
USA). Ten milligrams of 3,5-dimethoxy-4-hydroxycin-
namic acid were dissolved in 0.05% TFA of acetonitrile/
water (1:1) and used as matrix. Analytical high-perfor-
mance liquid chromatography (HPLC) was performed on a
Hewlett Packard 1050 HPLC system with a multiwave-
length detector and a flow-through Berthold LB 506 Cl γ-
detector (Regensdorf, Switzerland) using a Macherey-Nagel
Nucleosil 120 C18 column (Oensingen, Switzerland) (elu-
ents: A=0.1% TFA in water and B=acetonitrile; gradient:
0–20 min, 80%–50% A; 21–24 min, 100% B; 24–25 min,
80% A). Preparative HPLC was performed on a Metrohm
HPLC system LC-CaDI 22–14 (Herisau, Switzerland) with
a Macherey-Nagel VP 250/21 Nucleosil 100–5 C18 column
(eluents: A=0.1% TFA in water and B=acetonitrile;
gradient: 0–10 min, 70%–52% A; 11–14 min, 100% B;
14–15 min, 70% A). Quantitative γ-counting was per-
formed on a COBRA 5003 γ-system well counter from
Packard Instruments (Meriden, CT, USA). Solid phase
peptide synthesis was performed on a semiautomatic
peptide synthesiser commercially available from Rink
Combichem Technologies (Bubendorf, Switzerland). The
cell culture medium was Dulbecco’s minimal essential
medium (DMEM) with 10% or 1% foetal calf serum (FCS)
from BioConcept (Allschwil, Switzerland). PET imaging
was performed on a Siemens ECAT EXACT HR+ scanner
(Siemens/CTI, Knoxville, TN, USA), and scintigraphic
imaging was carried out on a PRISM 2000 XP camera
(Philips, the Netherlands). 68Ga was obtained from a
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68Ge/68Ga generator which consists of a column containing
a self-made phenolic ion exchanger loaded with 68Ge and
coupled in series with a small anion exchanger column (AG
1×8 Cl-1, mesh 200–400; Bio-Rad, Munich, Germany) to
concentrate 68Ga during elution [28].
Synthesis
DOTA-PESIN was synthesised on solid support as de-
scribed previously [17]. In brief, the peptide was assem-
bled on a Rink amide MBHA resin according to classical
Fmoc chemistry on a semi-automatic peptide synthesiser.
Trityl and tert-butoxycarbonyl were used as side chain-
protecting groups of His and Trp, respectively. Fmoc-
PEG4-OH (four equivalents) and DOTA-tris(tBu) ester
(three equivalents) were consecutively coupled to the
peptide with HATU [1.2 equivalents based on Fmoc-
PEG4-OH or DOTA-tris(tBu) ester] as activating agent.
Cleavage from the resin and deprotection as well as product
purification and identification were performed according to
a previously described protocol [17]. Calculated MW:
1573.81; MS-ES(−): 1610.3 [M+K−H]−, 804.8 [M+K−
2H]2−; MS-ES(+): 806.8 [M+K+2H]2+; MALDI, m/z (%):
1573.7 (100, [M+H]+), 1594.7 (5, [M+Na]+); HPLC
tR: 12.5 min on analytical HPLC (purity: >98%).
[GaIII/LuIII]-DOTA-PESIN A mixture of DOTA-PESIN
(0.5 μmol) in 500 μl 0.5 mol/l ammonium acetate buffer
(pH 5) was incubated with 1.5 μmol Ga(NO3)3·9H2O or Lu
(NO3)3·5H2O (in 0.04 mol/l HCl) at 95°C for 25 min, and
purified over a SepPak C18 cartridge (Waters Corp.,
Milford, MA) preconditioned with 10 ml ethanol and
10 ml water. The cartridge was eluted with 10 ml water
followed by 3 ml methanol, resulting in the metalIII-DOTA-
peptide after evaporation of methanol. The final product
was analysed by analytical HPLC and MALDI. [GaIII-
DOTA-PESIN (calculated MW): 1640.51; MALDI, m/z
(%): 1641.7 (100, [M+H]+), 1663.6 (20, [M+Na]+); HPLC
tR: 13.8 min. Purity: >99%. [Lu
III]-DOTA-PESIN (calcu-
lated MW): 1745.76; MALDI, m/z (%): 1745.8 (100,
[M+H]+), 1767.7 (10, [M+Na]+); HPLC tR: 14.1 min.
Purity: >99%.
Preparation of radiotracer for in vitro and in vivo studies
[177Lu]-DOTA-PESIN was prepared by dissolving 10 μg of
the peptide (6.35 nmol) in ammonium acetate buffer
(300 μl, 0.5 mol/l, pH 5.5); after addition of 177LuCl3
(2 mCi), the solution was incubated for 15 min at 95°C. A
1.5 molar excess of Lu(NO3)3·5H2O was added and
incubated again for 15 min. Subsequently, [177Lu]-DOTA-
PESIN was purified utilising a SepPak C18 cartridge
preconditioned with 10 ml methanol and 10 ml water; the
cartridge was eluted with 3 ml water, followed by 2ml ethanol
to yield pure [177Lu]-DOTA-PESIN. For biodistribution
studies, the labelling was performed accordingly without the
addition of cold Lu(NO3)3·5H2O. Oxidation of C-terminal
MetNH2 was suppressed by the addition of methionine. The
solution for injection was prepared by dilution with 0.9%
NaCl (0.1% BSA) to provide the radioligand solution.
[67Ga]-DOTA-PESIN was prepared in the same way. All
radiolabelled peptides were analysed with analytical HPLC
and showed a radiochemical purity of >97%.
Preparation of [68Ga]-DOTA-PESIN for PET imaging
The generator eluate containing ∼0.5 GBq 68Ga in 0.2 ml/
0.5 mol/l HCl was evaporated to dryness and redissolved in
0.2 ml acetate buffer (pH 4.8, 0.1 mol/l). After addition of
5 μl of a 1 mmol/l aqueous DOTA-PESIN solution, the
mixture was kept for 10 min at 90°C. The uncomplexed
68Ga was separated by adsorption onto a SepPak C18
cartridge that was equilibrated with 0.1 mol/l acetate buffer
(pH 6.2), whereas [68Ga]-DOTA-PESIN was eluted with
1.5 ml ethanol. After evaporation of the organic solvent, the
radiotracer was redissolved in 0.01 mol/l phosphate-buff-
ered saline (pH 7.4) containing 0.5 mg/ml human serum
albumin. The preparations were checked for bound and free
68Ga by paper chromatography using Whatman No.1 and
methanol/0.01 mol/l acetate buffer (pH 6.2) at a ratio of
55:45. 68Ge contamination of the [68Ga]-DOTA-PESIN
preparation was determined by gamma counting after a
decay period of ≥30 h.
Binding affinity and receptor subtype profile
Using [125I-D-Tyr4]BN as a GRP-R preferring ligand, the
IC50 values of [
natGa/natLu]-DOTA-PESIN were measured
in competitive binding experiments performed with in-
creasing concentrations of natGa/natLu-labelled peptides in
successive tissue sections containing tumours expressing
GRP-R [29].
The binding affinity profile for the three BN receptor
subtypes was determined as described in detail previously
[11, 30]. Human tumours were selected that have previ-
ously been shown to express predominantly one single BN
receptor subtype. IC50 values were determined in compet-
itive binding experiments performed with increasing
amounts of natGa/natLu-DOTA-PESIN using [125I-D-Tyr6,
β-Ala11, Phe13, Nle14]BN(6–14) as universal radioligand.
Cell culture
PC-3 cells (ECACC, Wiltshire SP4 OJG, UK) were cultured
in DMEM. DMEM was supplemented with vitamins,
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essential and non-essential amino acids, L-glutamine, anti-
biotics (penicillin/streptomycin), fungicide [amphotericin B
(Fungizone)] and 10% FCS.
Internalisation and efflux studies
Internalisation and externalisation experiments were per-
formed in six-well plates as described previously [17].
Briefly, approximately 3 kBq (0.25 pmol) of [177Lu/67Ga]-
DOTA-PESIN was added to PC-3 cell-containing incuba-
tion medium (0.5–1×106 cells per well) and incubated
at 37°C in a 5% CO2 environment at different time points
(0.5, 1, 2, 4 and 6 h). A large excess of [GaIII]-DOTA-
PESIN (0.4 μmol/l, 150 μl) was used to determine
non-specific internalisation. At each time point, the internal-
isation was stopped by removal of the medium followed by
washing the cells with ice-cold solution composed of 0.9%
NaCl/0.01 mol/l Na2HPO4/0.01 mol/l KH2PO4 (pH 7.2).
Cells were then treated (twice) with glycine buffer
(0.05 mol/l glycine solution, pH adjusted to 2.8 with
1 mol/l HCl) for 5 min to distinguish between cell
surface-bound (acid buffer removable) and internalised
(acid-resistant) radioligand. Finally, cells were detached
from the plates by incubation with 1 mol/l NaOH for
10 min at 37°C, and the radioactivity was measured in a
gamma counter. The percentage of added activity per
million cells (% of total) was calculated for internalisation
at each time point.
For externalisation studies, PC-3 cells were allowed to
internalise [177Lu/67Ga]-DOTA-PESIN for 2 h; they were
then exposed to an acid wash, as described in the internal-
isation experiments, to dissociate the cell surface-bound
radioligand. Then 1 ml of culture medium (1% FCS) was
added to each well, the cells were incubated at 37°C in a
5% CO2 environment and the externalisation of the cell-
incorporated radioactivity was studied at different times.
The culture medium was collected and measured for ra-
dioactivity. The percentage of total internalised radiotracer
was calculated for efflux.
Biodistribution experiments in PC-3 tumour-bearing
nude mice
After a slight anaesthesia with isoflurane in an air/oxygen
mixture, athymic nude female mice (Harlan, the Nether-
lands) were implanted subcutaneously on the right flank
with about 10 million PC-3 tumour cells, which were
freshly expanded in 100 μl sterilised PBS solution.
Seven to ten days after inoculation the tumours weighed
60–130 mg and the mice were injected via the tail vein with
10 pmol radiolabelled peptide (about 0.12 MBq [67Ga]-
DOTA-PESIN), diluted in 0.9% NaCl (0.1% BSA, pH 7.4,
total injected volume 100 μl). For the determination of non-
specific uptake in the tumour and receptor-positive organs,
a group of four animals was injected with a mixture of
10 pmol radiolabelled peptide/50 μg [GaIII]-DOTA-PESIN
in 0.9% NaCl solution (injected volume, 150 μl). To study
the biodistribution of [67Ga]-DOTA-PESIN, mice were
sacrificed at 1, 4 and 24 h post injection; the organs of
interest were collected, rinsed of excess blood, blotted,
weighed and counted in a γ-counter. The percentage of
injected activity per gram (%IA/g) was calculated for each
tissue. The total counts injected per animal were determined
by extrapolation from counts of an aliquot taken from the
injected solution as a standard. For the biodistribution study
of [177Lu]-DOTA-PESIN, mice were sacrificed at 4, 24, 48
and 72 h post injection.
To study the influence of lysine, 15 mg lysine was co-
injected with 10 pmol [67Ga]-DOTA-PESIN in 150 μl, and
the animals were sacrificed at 4 h post injection.
Biodistribution studies with [67Ga]-DOTA-PESIN were
also performed at the German Cancer Research Centre
under conditions of PET imaging with [68Ga]-DOTA-
PESIN. Six- to 8-week-old female Swiss CD1 nu/nu mice
were inoculated with a PC-3 tumour in the right flank.
Eleven to thirteen days later, tumours weighing 70–175 mg
were ready for experiment. Fifteen pmol (0.61 MBq)
[67Ga]-DOTA-PESIN was injected into the lateral tail vein.
Mice were sacrificed at 1 h p.i. and organs of interest
collected for measurement as described previously [31].
PET imaging with [68Ga]-DOTA-PESIN
PET imaging was performed on a Siemens ECAT EXACT
HR+ scanner (Siemens/CTI, Knoxville, TN, USA), and
PET data were acquired in 3D mode and reconstructed
iteratively with a full 3D algorithm from a 256×256 matrix
for viewing transaxial, coronal and sagittal slices of
0.57 mm thickness. Pixel size was 1.14 mm and transaxial
resolution obtained was 2.8 mm. For imaging studies, an
awake female CD1 nu/nu mouse that was inoculated with a
PC-3 tumour on the right flank was lightly restrained and
injected with 1.94 MBq, 15 pmol [68Ga]-DOTA-PESIN via
a lateral tail vein. One hour later the mouse was
anaesthetised with isoflurane in an air/oxygen mixture and
sacrificed, then positioned in the tomograph symmetrically
in the centre of the field of view. Acquisition of PET data
was obtained with a 30-min emission and a 10-min
transmission scan.
Scintigraphy with [177Lu]-DOTA-PESIN
Scintigraphic imaging of PC-3 tumour xenografts was
performed on a PRISM 2000 XP camera. Two mice were
inoculated with a PC-3 tumour on the right hind leg. After
16 days the tumours had grown enough for imaging. Both
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animals were lightly restrained and injected with 13.5 MBq,
0.32 nmol [177Lu]-DOTA-PESIN via a lateral tail vein; one
of them was co-injected with 50 μg [GaIII]-DOTA-PESIN.
Four hours after injection, the animals were anaesthetised
with isoflurane in an air/oxygen mixture and positioned on
the head of the camera symmetrically in the centre of the
field of view while anaesthesia was monitored by observing
the breath frequency. Scans were taken 15 min after
anaesthesia at 4, 24, 48 and 72 h post injection.
All animal experiments were performed in compliance
with the Swiss regulations for animal treatment (Bundesamt
für Veterinärwesen, approval no. 789), or with the German
laws for the protection of animals.
Statistical analysis
Data are expressed as mean ± SD, which were calculated on
Microsoft Excel. Student’s t test (Origin 6, Microcal
Software, Inc., Northampton, MA) was used to determine
statistical significance at the 95% confidence level with
p<0.05 being considered significantly different.
Results
Synthesis and radiolabelling
DOTA-PESIN (Fig. 1) was synthesised using Fmoc
strategy, affording yields of 45% based on the removal of
the first Fmoc group; the purity analysed by HPLC was
≥97%. DOTA-PESIN and [GaIII/LuIII]-DOTA-PESIN were
characterised by electrospray and MALDI TOFF mass
spectrometry. Radiolabelled DOTA-PESIN was prepared by
incubation with 67/68GaCl3 or
177LuCl3 at elevated temper-
ature. The labelling yield of [67/68Ga]-DOTA-PESIN was
≥98% at specific activities of >129 GBq μmol−1 for 68Ga
and >12 GBq μmol−1 for 67Ga, respectively. The radiolytic
oxidation of methionine in [177Lu]-DOTA-PESIN was
about 2% when the specific activity was ≤11.6 GBq μmol−1
and reached 26% at 60 GBq μmol−1. With optimisation of
the labelling conditions, labelling yields of ≥95% of
[177Lu]-DOTA-PESIN were achieved at a specific activity
of >85 GBq μmol-1 in the presence of 400 μg methionine
per 370 MBq 177Lu.
Receptor binding affinity and profile
Table 1 shows the GRP-R binding affinities of DOTA-
PESIN and its respective metallopeptides to human cancer
tissue overexpressing GRP-R, as determined by a compet-
itive binding assay using [125I-Tyr4]BN as radioligand. On
the human GRP-R, the IC50 values were 9.5±3.4 nmol/l for
DOTA-PESIN and 6.1±3.0 nmol/l and 6.6±0.1 nmol/l for
the LuIII- and GaIII-complexed peptides, respectively. There
was no significant difference on the mouse GRP-R.
[GaIII]-DOTA-PESIN and [LuIII]-DOTA-PESIN were
also studied with respect to the BN receptor subtype profile
using human cancer tissue shown to express predominantly
a single BN receptor subtype. Using [125I-D-Tyr6, β-Ala11,
Phe13, Nle14]BN(6–14) as radioligand, the binding studies
showed good binding affinities to NMB-R and GRP-R, and
no affinity to BB3-R.
Internalisation and efflux studies
Internalisation of both radiopeptides was followed for 6 h.
Both 177Lu- and 67Ga-labelled DOTA-PESIN showed
specific and time-dependent cell uptake, reaching 39.1±
1.1% and 43.7±1.8% of the total amount added to the
medium, respectively, after 6 h of incubation at 37°C
(Fig. 2). Within the first 2 h of incubation [177Lu]-DOTA-
PESIN internalised somewhat faster than [67Ga]-DOTA-
PESIN but after 4 h there was no statistical difference. The
efflux kinetics (Fig. 3) showed a cellular retention of 52.5±
1.6% of the total internalised activity 20 h after start of
efflux for both radiopeptides.
Animal biodistribution studies
Biodistribution studies using the 67Ga/177Lu-labelled pep-
tides were performed with athymic nude female mice
bearing the PC-3 human prostate tumour; the results are
presented in Tables 2 and 3 as percentage of injected
activity per gram of tissue (%IA/g).
According to Table 2, [67Ga]-DOTA-PESIN and [177Lu]-
DOTA-PESIN (data in parentheses in the following)
displayed rapid blood clearance from the PC-3-bearing
mice, with 0.47±0.06 %IA/g at 1 h and 0.11±0.04 (0.04±
0.01) %IA/g at 4 h post injection. Both radiotracers were
N N
NN
HO O O
OHOHO O
OOOO
H
N Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2
O
Fig. 1 Structural formula of
DOTA-PESIN
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quickly washed out from the GRP-R-negative tissues
except the kidneys. [67Ga/177Lu]-DOTA-PESIN also
showed high uptake in the human prostate tumour
xenograft and in the mouse GRP-R-positive organs, e.g. at
4 h the tumour uptake was 8.77±1.88 (7.46±1.64) %IA/g
and the pancreas uptake 43.8±6.9 (39.0±4.9) %IA/g. In
vivo competition experiments (Table 2) involving co-
injection of 50 μg [GaIII]-DOTA-PESIN with [67Ga]-
DOTA-PESIN resulted in a >94% reduction of uptake in
the tumour and also in a reduction of uptake in other GRP-
R-positive organs, e.g. >95% in the pancreas and 97% in
the pituitary, 83–85% in the adrenals, spleen and bowel,
and 78% in the stomach, showing specific receptor-
mediated uptake in these tissues. The injection of the
blocking dose had no significant influence on the uptake in
other non-target organs whereas it led to a somewhat
decreased kidney uptake. Co-injection of lysine did not
reduce the kidney uptake, and the ratio between tumour and
kidney remained almost unchanged. The impact of the
blocking dose on biodistribution of [177Lu]-DOTA-PESIN
can be seen from the scans shown in Fig. 6.
Due to the rapid clearance from the body, high tumour-
to-background ratios were found (Table 3). These ratios
increased with time. For instance, the ratios of [67Ga]-
DOTA-PESIN between tumour and blood (muscle) varied
from 31 (62) to 211 (237) during 1 h to 24 h post injection;
for [177Lu]-DOTA-PESIN, the respective ratios were 201
(147) at 4 h, 215 (387) at 24 h and 715 (486) at 72 h post
injection. Both radiotracers also displayed high tumour-to-
kidney and tumour-to-liver ratios (in parentheses): 2.4–2.6
(22–23) for the 67Ga-labelled and 1.7–3.6 (36–52) for the
177Lu-labelled peptide.
The pharmacokinetics (Fig. 4) of [67Ga]-DOTA-PESIN
shows the potential to visualise the tumour very early owing
to the high initial accumulation, which reached 14.8±2.4 %
IA/g at 1 h p.i. (9.40±1.39 %IA/g with an injected dose of
15 pmol and a different mouse strain), decreased to 8.77±
1.88 %IA/g at 4 h and was still 6.76±0.29 %IA/g at 24 h.
[177Lu]-DOTA-PESIN also displayed a high uptake in the
tumour and a relatively slow washout: 7.46±1.64 %IA/g
at 4 h, 5.81±0.40 %IA/g at 24 h, 4.05±0.23 %IA/g at
Table 1 IC50 values for metallated DOTA-PESIN when competed with [
125I-Tyr4]BN against the human and mouse GRP-R and affinity profiles
using [125I-Tyr6, β-Ala11, Phe13, Nle14]BN(6–14)
Compound Human GRP-R Mouse GRP-R BN receptor subtypes
NMB-R GRP-R BB3-R
DOTA-PESIN 9.5±3.4 (3) ND ND ND ND
[LuIII]-DOTA-PESIN 6.1±3.0 (3) ND 15.0±4.0 (2) 8.3±1.7 (2) >1,000 (2)
[GaIII]-DOTA-PESIN 6.6±0.1 (3) 7.0±1.2 (3) 12.5±0.5 (2) 10.0±0.0 (2) >1,000 (2)
IC50 values (nmol/l±SE) are in triplicates. Numbers of independent studies are listed in parentheses
ND not determined
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48 h and 2.43±0.12 %IA/g at 72 h. In the pancreas,
[177Lu]-DOTA-PESIN was released faster than the 67Ga-
labelled peptide. In addition, the release of [177Lu]-DOTA-
PESIN from the pancreas and kidneys was faster than from
the tumour, leading to an increasing tumour-to-organ ratio
with time.
PET imaging
Iteratively reconstructed PET images of PC-3 tumour
xenografts with [68Ga]-DOTA-PESIN (1.94 MBq, 15 pmol)
were performed at 1 h post injection (Fig. 5). The PC-3
tumour was located in the thoracic wall, and was
perceptible with clear contrast from the adjacent back-
ground in the transaxial slices. Coronal slices distinctly
show the tumour and kidneys. Sagittal slices demon-
strate that [68Ga]-DOTA-PESIN accumulates predomi-
nantly in the PC-3 tumour, pancreas and kidneys. The
results of direct tissue counting and of PET imaging were
consistent.
Scintigraphy
Figure 6 shows the scintigraphic imaging of PC-3 tumour
xenografts with [177Lu]-DOTA-PESIN (left: unblocked;
right: blocked with 50 μg [GaIII]-DOTA-PESIN). Imaging
was performed at 4, 24, 48 and 72 h after injection. In the
blocked mouse the tumour could not be visualised and only
the kidneys were visible, whereas the PC-3 tumour of the
non-blocked mouse was visualised with clear contrast from
the adjacent background at all time points. Prominent
uptake was also observed in the pancreas and kidneys.
The imaging kinetics showed that [177Lu]-DOTA-PESIN
was preferably retained in the tumour rather than in the
Table 2 Biodistribution analysis (%IA/g ± SD) of 67Ga and 177Lu-labelled DOTA-PESIN in PC-3 tumour-bearing nude mice
Site 67Gaa 67Gab 177Lub
1 h 1 h 4 h 4 h blockedc 4 h lysined 4 h
Blood 0.556±0.120 0.471±0.060 0.108±0.041 0.103±0.029 0.235±0.012 0.037±0.011
Muscle 0.160±0.046 0.243±0.170 0.042±0.008 0.043±0.004 0.068±0.014 0.051±0.015
Adrenals NC 20.6±2.1 15.8±3.2 2.80±2.59 16.1±2.4 15.3±3.4
Pancreas 47.7±4.7 65.3±8.7 43.8±6.9 2.26±2.00 54.8±8.3 39.0±4.9
Spleen 2.62±0.28 2.67±0.47 2.25±0.16 0.48±0.05 2.36±0.10 2.55±0.55
Kidney 4.27±0.66 6.27±0.94 3.36±0.47 2.09±0.27 4.67±0.97 4.67±0.78
Stomach NC 4.77±0.65 1.72±0.86 0.39±0.28 2.39±0.21 1.68±0.43
Bowel 7.23±0.66 7.41±0.79 3.65±1.55 0.57±0.47 5.75±1.21 3.77±1.30
Liver 0.50±0.10 0.64±0.15 0.41±0.06 0.44±0.15 0.37±0.03 0.21±0.04
Lung 0.60±0.12 0.69±0.16 0.41±0.16 0.19±0.05 0.22±0.03 0.10±0.04
Heart NC 0.31±0.08 0.06±0.01 0.06±0.01 0.12±0.01 0.06±0.01
Bone 0.35±0.06 0.60±0.20 0.40±0.14 0.22±0.10 0.62±0.07 0.48±0.06
Pituitary NC 18.7±9.8 3.35±1.62 0.09±0.08 3.07±0.77 3.44±0.53
Tumour 9.40±1.39 14.8±2.5 8.77±1.88 0.52±0.21 8.87±1.1 7.46±1.63
Results are the mean of groups of four to eight mice
NC not collected
a PC-3 tumour-bearing CD nude mice were used for the biodistribution of 15 pmol (0.61 MBq) [67 Ga]-DOTA-PESIN
b 10 pmol [67 Ga/177 Lu]-DOTA-PESIN was injected to PC-3 tumour-bearing athymic nude mice
c Blocked by co-injection of 50 μg [GaIII ]-DOTA-PESIN
d Co-injection of 15 mg lysine per mouse
Table 3 Radioactivity ratios
between PC-3 tumour and
other organs of 67Ga- and
177Lu-labelled DOTA-PESIN
in PC-3 tumour-bearing female
athymic nude mice [8≥n≥4]
Tumour-to-blocked tumour ra-
tio (4 h)=16.9
Time (h) Blood Muscle Kidney Liver
67Ga 177Lu 67Ga 177Lu 67Ga 177Lu 67Ga 177Lu
1 31 62 2.4 23
4 81 201 209 147 2.6 1.7 22 36
24 211 215 237 387 2.4 2.5 23 43
48 476 488 3.1 52
72 715 486 3.6 48
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pancreas and kidneys. These imaging results are consistent
with biodistribution data (Fig. 4).
Discussion
We report on the development of a radiopeptide which can
be used in SPECT (67Ga), PET (68Ga) and targeted
radionuclide therapy (177Lu) of BN receptor-positive
tumours such as prostate and breast cancer or gastrointes-
tinal stromal tumours. As part of a small library of peptides,
which differ by the spacer between the chelate and the
pharmacophoric peptide, DOTA-PEG4-BN(7–14) appeared
to have promising properties in terms of a relatively high
tumour-to-kidney and tumour-to-liver ratio. Therefore we
decided to study this peptide in depth after labelling with
67Ga, 68Ga and 177Lu with the aim of introducing these
radiopeptides into the clinic. DOTA (1,4,7,10-tetraazacy-
clododecane-1,4,7,10-tetraacetic acid) was chosen as che-
lator since it forms M3+ complexes with high in vitro and in
vivo stability [32]. PEG4 (15-amino-4,7,10,13-tetraoxapen-
tadecanoic acid) was chosen as spacer and pharmacokinetic
modifier. Very long PEG-based spacers (>3,000 D) cou-
pled to peptides or antibodies appear to decrease the
binding affinity of these biomolecules to their receptors
and to lower the rate of internalisation significantly, as
shown by Rogers et al. using a [64Cu]-DOTA-PEG-BN
(7–14) derivative [33]. Smaller versions do not seem to
have a sufficient influence on the pharmacokinetics and
hydrophilicity [31, 33].
The presented peptide was synthesised on solid phase
with an overall yield of >45%. 68Ga labelling was straight-
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Fig. 4 Kinetics of 67Ga-labelled (■) and 177Lu-labelled (○) DOTA-PESIN in PC-3 tumour-bearing mice (left, pancreas; middle, PC-3 tumour;
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Fig. 5 Iteratively reconstructed
PET images of PC-3 tumour
xenograft with [68Ga]-DOTA-
PESIN (1.94 MBq, 15 pmol)
performed at 1 h post injection.
The transaxial slice shows the
PC-3 tumour (right flank) to be
located in the thoracic wall. The
coronal slice shows a clear
distinction between tumour and
kidneys. The sagittal slice
demonstrates that [68Ga]-
DOTA-PESIN accumulates
predominantly in the
PC-3 tumour, pancreas
and kidneys
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forward and afforded high radiochemical yields at a
reasonable specific activity of ≥130 GBq μmol-1, which
allowed production of good PET images at 1 h post
injection. Sagittal slices clearly showed that [68Ga]-DOTA-
PESIN mainly localises the PC-3 tumour, the GRP receptor-
positive pancreas and the kidneys.
Binding studies using the GRP receptor ligand [125I-
Tyr4]BN revealed medium affinity of [GaIII]-DOTA-PESIN
and [LuIII]-DOTA-PESIN to the human GRP receptor and
no difference between human and mouse GRP receptors, at
least for [GaIII]-DOTA-PESIN. The affinity to the three
human BN receptor subtypes using the universal radio-
ligand [125I-D-Tyr6, β-Ala11, Phe13, Nle14]BN(6–14)
showed that both metallopeptides have good to moderate
affinity to the GRP and the NMB receptor and no affinity to
the BB3 receptor. The affinities are about ten times lower
than those of truncated BN(7–14) and intact BN derivatives
coupled to bifunctional tetra-amines, which show IC50
values between 0.2 and 2 nmol/l to the GRP receptor and,
with one exception, also to the NMB receptor. The best of
the 99mTc-labelled compounds have Kd values and IC50
values below 1 nmol/l [19]. There was no significant
difference in affinity between the peptides metallated with
Ga3+ or Lu3+. This is in contrast to DOTA-octreotide
derivatives; these conjugates show a distinctly improved
binding affinity when labelled with radiogallium [32, 34].
The rate of internalisation into PC-3 cells was similar for
the two radiopeptides and somewhat more efficient than the
internalisation of the panbombesin ligands studied previ-
ously in the same assay and under the same conditions [17].
This similarity does not reflect the distinct difference in
binding affinity. The high rate of internalisation of the two
radiopeptides indicates that they are agonists.
Efflux curves of [67Ga]-DOTA-PESIN and [177Lu]-
DOTA-PESIN from the PC-3 cells after 2 h of internal-
isation are essentially identical and their half-lives are
≥20 h, which is much longer than those of the panbombesin
derivatives. Efflux studies were also performed with [177Lu-
DOTA-Aoc]BN(7–14) but only up to 2 h [18]. Within this
time period the two compounds behave similarly. [67Ga-
DOTA0-PEG2, D-Tyr
6, β-Ala11, Thi13, Nle14]BN(7–14) and
the corresponding 177Lu-labelled radiopeptide externalise
Fig. 6 Scintigraphic images of
[177Lu]-DOTA-PESIN in PC-3
tumour-bearing mice at 4, 24, 48
and 72 h post injection
(13.5 MBq, blocked with 50 μg
[GaIII]-DOTA-PESIN. Left,
unblocked; right, blocked)
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with a somewhat different rate (t1/2 (
67Ga)=16.5±2.4 h; t1/2
(177Lu)=12.8±1.4 h) [31]. A prolonged intracellular reten-
tion is of importance if long-lived radionuclides are to be
used in therapy studies.
After administration of [67Ga/177Lu]-DOTA-PESIN,
clearance from the circulation was fast and whole body
clearance proceeded via the urinary system, unlike the
positively charged 99mTc-N4-labelled BN analogues, which
are partly excreted via the hepatobiliary tract [19, 27].
Clearance from GRP receptor-negative tissues was also
rapid except from the kidneys.
Initially, tumour uptake was very high (14.8% IA/g at
1 h), approaching the uptake of the best radiopeptides
studied so far in the PC-3 tumour model [27]. This new
radiopeptide has a high tumour-to-liver ratio which may
make it even somewhat superior to the best 99mTc-labelled
peptides [19]. The uptake in tumour, pancreas, intestine and
pituitary was specific and receptor mediated, as shown by
the co-injection of cold peptide, indicating that these organs
are also GRP receptor positive. Unlike others [16, 35, 36]
we also found a decrease in the kidney uptake when a
peptide-blocking dose was administered, whereas a sub-
stantial reduction in kidney uptake upon blocking was also
shown recently by use of an 18F-labelled Lys3-BN
derivative [37]. The fast background clearance of the
radiogallium peptide renders [68Ga]-DOTA-PESIN an ideal
radiotracer for PET imaging. The relatively fast initial
washout from the tumour may be explained by radioligand
not being internalised and being metabolised during its
presence in the tumour compartment.
The structural entities which confer the suitable pharma-
cokinetic properties to this molecule most likely reside in
the PEG4 spacer. Preliminary data using shorter and longer
spacers indicate that PEG4 has an optimal length. The lack
of affinity to the BB3 receptor may be advantageous as this
orphan receptor is expressed in the human pancreas.
Conclusion
Despite the relatively low binding affinity of [LuIII, GaIII]-
DOTA-PESIN the corresponding radiopeptides show suit-
able pharmacokinetics in the PC-3 tumour-bearing mouse
model, with high tumour uptake and relatively slow
washout from the tumour. The radiopeptides show superior
tumour-to-liver and suitable tumour-to-kidney ratios in
comparison with our earlier published radiopeptides and
even with the best 99mTc-labelled BN analogues. This
renders the new peptides suitable for clinical studies.
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